Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Alexander H. Song"'
Autor:
Kimberly M. Burcher, Chance H. Bloomer, Elena Gavrila, John M. Kalada, Mark J. Chang, Rediet R. Gebeyehu, Alexander H. Song, Lara M. Khoury, Thomas W. Lycan, Rebecca Kinney, Ralph D’Agostino, Paul M. Bunch, Kirtikar Shukla, Pierre Triozzi, Cristina M. Furdui, Wei Zhang, Mercedes Porosnicu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Immunotherapy with programmed death receptor-1 (PD-1) inhibitors, as a single agent or in combination with chemotherapy, is the standard first-line treatment for recurrent or metastatic head and neck squamous cell cancer (R/M HNSCC). Unfo
Externí odkaz:
https://doaj.org/article/4b2b3487d94347f3b131d6d499c50ee5
Autor:
Lara M. Khoury, Kimberly M. Burcher, Ronald T. Ng, Alexander H. Song, Mark J. Chang, Elena Gavrila, Chance H. Bloomer, Mac B. Robinson, Brian E. Kouri, Joshua D. Waltonen, Paul M. Bunch, Ulrich M. Lauer, Mercedes Porosnicu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Immune checkpoint inhibitors (ICIs) are the current guideline recommended treatment for many malignancies considered to be terminal. Despite considerable advances, their utility remains limited, and the field requires synergistic partners to further
Externí odkaz:
https://doaj.org/article/483654dff18f4ed9bb6231e345b4dea5
Autor:
Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, Wei Zhang, Mercedes Porosnicu
Publikováno v:
Cancers, Vol 13, Iss 22, p 5733 (2021)
Failure to predict response to immunotherapy (IO) limited its benefit in the treatment of head and neck squamous cell cancer (HNSCC) to 20% of patients or less. Biomarkers including tumor mutational burden (TMB) and programmed death ligand-1 (PD-L1)
Externí odkaz:
https://doaj.org/article/a7f390719f544458b4a07425f2995346
Autor:
Kimberly M. Burcher, Andrew T. Faucheux, Jeffrey W. Lantz, Harper L. Wilson, Arianne Abreu, Kiarash Salafian, Manisha J. Patel, Alexander H. Song, Robin M. Petro, Thomas Lycan, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, Wei Zhang, Mercedes Porosnicu
Publikováno v:
Cancers, Vol 13, Iss 13, p 3118 (2021)
PARP inhibitors are currently approved for a limited number of cancers and targetable mutations in DNA damage repair (DDR) genes. In this single-institution retrospective study, the profiles of 170 patients with head and neck squamous cell cancer (HN
Externí odkaz:
https://doaj.org/article/99f431689f504bd687fe9e50f3905c75
Autor:
Alexander H. Song, Robin M. Petro, M. Porosnicu, Arianne Abreu, Kiarash Salafian, Ralph B. D'Agostino, Harper L. Wilson, Manisha Jayandra Patel, Cristina M. Furdui, Thomas Lycan, Umit Topaloglu, Wei Zhang, Kimberly M. Burcher, Andrew T. Faucheux, Jeffrey Lantz
Publikováno v:
Cancers, Vol 13, Iss 3118, p 3118 (2021)
Cancers
Volume 13
Issue 13
Cancers
Volume 13
Issue 13
Simple Summary The DNA damage repair (DDR) gene profile is largely unexplored in head and neck squamous cell cancer (HNSCC), leaving little known about the treatment of HNSCC with PARP inhibitors. In this retrospective study, the prevalence of mutate
Autor:
Alexander H. Song, Jack T. Burcher, Umit Topaloglu, Paul M. Bunch, Wei Zhang, Kimberly M. Burcher, Ryan T. Hughes, Elena Gavrila, Clayton Jackson, Thomas Lycan, Arianne Abreu, Ralph B. D'Agostino, M. Porosnicu, Andrew T. Faucheux, Jeffrey Lantz, Amy Xie, Cristina M. Furdui
Publikováno v:
Cancers
Volume 13
Issue 22
Cancers, Vol 13, Iss 5733, p 5733 (2021)
Volume 13
Issue 22
Cancers, Vol 13, Iss 5733, p 5733 (2021)
Simple Summary Immunotherapy has prompted a dramatic change in the management of head and neck squamous cell carcinoma (HNSCC), but the percentage of patients benefiting from treatment is limited to 20% or less. The application of precision oncology
Autor:
Manisha Jayandra Patel, Alexander H. Song, Wei Zhang, Arianne Abreu, Ralph B. D'Agostino, Andrew T. Faucheux, Kimberly M. Burcher, Umit Topaloglu, M. Porosnicu, Cristina M. Furdui, Jeffrey Lantz
Publikováno v:
Journal of Clinical Oncology. 39:e18016-e18016
e18016 Background: Next generation sequencing (NGS) has introduced the opportunity for targeted therapies and guidance regarding disease course and prognosis. The mutational landscape of squamous cell cancers of the head and neck (HNSCC) remains inco
Autor:
Colin L. Sweeney, Jocelynn R. Pearl, David Paschon, Sherry Koontz, Andreas Reik, Fyodor D. Urnov, Uimook Choi, Suk See De Ravin, Alexander H. Song, Xiaolin Wu, Janet Lee, Castle Raley, Kol A. Zarember, Andy Chan, Linhong Li, Philip D. Gregory, Ling Su, Hannah Newcombe, Pei-Qi Liu, David A. Shivak, Harry L. Malech, Madhusudan Peshwa, Narda Theobald
Publikováno v:
Nature biotechnology
Gene therapy with genetically modified human CD34(+) hematopoietic stem and progenitor cells (HSPCs) may be safer using targeted integration (TI) of transgenes into a genomic 'safe harbor' site rather than random viral integration. We demonstrate tha
Autor:
Edward J. Rebar, Fyodor D. Urnov, Andrea Mich, David Paschon, Daniel E. Bauer, Michael C. Holmes, Gary Lee, Alexander H. Song, Andreas Reik, John A. Stamatoyannopoulos, Sarah J. Hinkley, Colleen M. O'Neil, Thalia Papayannopoulou, Nikoletta Psatha, Stuart H. Orkin, Yuri R. Bendana, Yuanyue Zhou, Lei Zhang, Sandra Stehling-Sun, Pei-Qi Liu, Kai Hsin Chang, George Stamatoyannopoulos, Philip D. Gregory, Jeff Vierstra
Publikováno v:
Nature methods
Regulatory regions harbor multiple transcription factor recognition sites; however, the contribution of individual sites to regulatory function remains challenging to define. We describe a facile approach that exploits the error-prone nature of genom